A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.
An SEC filing shows an activist investor is building a sizable position in the company.
The company's promising immunotherapy approach delivered impressive data in multiple studies.
The lab equipment and services provider reduced full-year fiscal 2019 revenue guidance. Is today's tumble just a big overreaction?
The genetic testing pioneer lost $500 million in value after reporting fiscal Q3 operating results.
Management has a plan to make the company one of the lowest-cost producers in the industry. Will it work?
The FDA has given the company's lead drug platform a potential leg up in development.
The gene therapy developer appears to be struggling to find a safe and effective dose of its experimental Duchenne muscular dystrophy treatment.
Don't let a historically expensive stock market get you down. Give these three bargain stocks a look.
Forty-four states have brought a lawsuit against the industry.
The water utility announced a solid Q1 performance and reiterated full-year guidance, but the real excitement lies in the pending merger with Peoples.
The all-important Cobre Panama project remains on track, but it had nothing to do with a strong start to 2019.
The lithium segment struggled to overcome weather events in Chile, but the company's more mature businesses helped to partially offset the headwind.
Management increased its expectations for revenue, adjusted EBITDA, and adjusted earnings for the year ahead compared to initial guidance.
There are risks to having only one marketed drug product.
The company reported confusing top-line results from an important batch of phase 3 safety studies. Were they successful?
Efforts to develop the company's Nevada mines are proving costly.
Management thinks the company is on track for $500 million in revenue in 2020, but achieving that will require considerable capital investment.
The pharma announced first-quarter 2019 operating results.
Investors reacted with dismay over the terms of a license agreement.